Optimization of Therapeutic Drug Monitoring in Pediatric Kidney Transplant

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1+
SponsorChildren's Hospital Medical Center, Cincinnati

About this trial

The goal of this observational, pharmacokinetic study is to evaluate factors that change drug exposure in pediatric kidney transplant recipients so investigators can make better dosing decisions. The main question it aims to answer is:

Can investigators quantify the impact of factors that change with time (like food intake and medication adherence) on tacrolimus and mycophenolate? Our hypothesis is that inconsistent drug and food intake will increase day to day variability in drug exposure, and investigators can use this information to help us make decisions about what is the best dose.

Participants will participate in the study on 7 days over the course of 1 year. On day 1, participants will be asked questions to see if participants are able to be in this study. Investigators will ask what immunosuppression participants are taking, how tall and how much participants weigh.

On day 2, participants and their parent/guardian will be taught how to use the device to collect the blood samples and decide on which days to collect them.

On days 3-6, participants will collect blood samples 4 separate times over about 1 year. Collection days should try to be scheduled every 3 months (+/- 2 weeks).

On each collection day, participants will collect a sample 7 different times over 9 hours. Each collection will only take approximately 5 minutes. Participants will be asked to collect a blood sample immediately before the morning dose of tacrolimus or mycophenolate, and 20 min, 1hr, 3hr, 4hr, 6hr, 9hr after the dose.

Also on collection days, participants will receive text messages and be asked to complete different assessments about their medications, diet, and how they feel by responding to the texts.

On day 7, participants will have the opportunity to participate in an interview where investigators will ask about participants' experience in the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Recipient of a solid organ transplant and at least 1 year of age

Receiving tacrolimus and/or mycophenolate

Patient and/or caregiver is willing to receive text notifications and has a mobile device capable of receiving and sending text and multimedia messages.

Ability to understand and willingness to sign a written informed consent

Disqualifiers

History of allergy to tape adhesives

Trial population

Cincinnati Children's Hospital

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

25 Participants
are grouped into 1 trial group
Group A: Longitudinal Self-Sampling for Immunosuppression Pharmacokinetics

Trial outcomes

Primary outcomes

1

Tacrolimus AUC

Tacrolimus AUC (total exposure) will be estimated from the 7 tacrolimus blood concentrations using a population pharmacokinetic model

Time frame
From enrollment for 1 year (samples every 3 months)
2

Mycophenolic acid AUC

Mycophenolic acid AUC (total exposure) will be estimated from the 7 tacrolimus blood concentrations using a population pharmacokinetic model

Time frame
From enrollment for 1 year (samples collected every 3 months)

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: